Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 11.05.2026 2 BJU Int 1 Endocrinology 1 Eur J Radiol 1 Eur Urol 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 2 J Nucl Med 1 Magn Reson Imaging 2 Nat Rev Urol 1 Oncogene 1 PLoS Genet 2 PLoS One 2 Proc Natl Acad Sci U S A 13 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. TRINER D, Ginsburg KB, Moser A, Labardee C, et al
   Urologist and radiologist contributions to variation in prostate cancer detection at fusion biopsy.
   BJU Int. 2026 May 7. doi: 10.1111/bju.70308.
   PubMed         Abstract available
   
   
2. SHARIFI SHH, Williams A, Ryan JT, Ajami T, et al
   Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.
   BJU Int. 2026 May 6. doi: 10.1111/bju.70303.
   PubMed         Abstract available
   
   

   
   Endocrinology

3. SINGH N, Heemers HV
   Breaking the bonds: targeting protein dimerization for prostate cancer therapy.
   Endocrinology. 2026 May 5:bqag056. doi: 10.1210.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

4. KADIRLI K, Canturk A
   Real-world text-only inference of PI-RADS v2.1 from prostate MRI reports using large language models: a lesion-level, zone-aware study.
   Eur J Radiol. 2026;200:112838.
   PubMed         Abstract available
   
   

   
   Eur Urol

5. NGUYEN DD, Tadayon Najafabadi B, Lin L, Kwong JCC, et al
   Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
   Eur Urol. 2026 May 5:S0302-2838(26)02107-X. doi: 10.1016/j.eururo.2026.
   PubMed         Abstract available
   
   

   
   Int J Radiat Oncol Biol Phys

6. MULVANEY O, Chung JS, Kobayashi M, Somatilaka BG, et al
   GPNMB(+) MDSCs Mediate Radiation-Induced Immune Suppression in Prostate Cancer and Are Targetable to Improve Systemic Control.
   Int J Radiat Oncol Biol Phys. 2026 Apr 30:S0360-3016(26)00656.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

7. MCKAY RR, Xie W, Ajmera A, Araneta A, et al
   Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
   J Clin Oncol. 2026 May 7:JCO2502835. doi: 10.1200/JCO-25-02835.
   PubMed         Abstract available
   
   

   
   J Natl Cancer Inst

8. POST LM, Hurwitz L, Fisher JA, Kaufman JD, et al
   Outdoor air pollution and prostate cancer risk in the NIH-AARP diet and health study.
   J Natl Cancer Inst. 2026 May 7:djag137. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Nucl Med

9. KIMURA K, Murthy V, Voter AF, Solnes LB, et al
   PSMA PET/CT-Derived Indicators and Outcomes After [(177)Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program.
   J Nucl Med. 2026 Feb 12:jnumed.125.270789. doi: 10.2967/jnumed.125.270789.
   PubMed         Abstract available
   
   
10. ULANER GA, Lam R
    Widespread Prostate Cancer Osseous Metastases: Negative on (18)F-Piflufolastat PET but Positive on (18)F-Fluciclovine PET.
    J Nucl Med. 2026 May 6:jnumed.125.272001. doi: 10.2967/jnumed.125.272001.
    PubMed        
    
    

    
    Magn Reson Imaging

11. KOVACS B, Zhang KS, Baumgartner M, Hielscher T, et al
    Incorporating functional soft tissue deformations in AI model training for spatially accurate prostate cancer detection.
    Magn Reson Imaging. 2026 May 5:110698. doi: 10.1016/j.mri.2026.110698.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

12. SCHAFFER KR, Markowski MC
    Managing patients with recurrent prostate cancer who refuse ADT.
    Nat Rev Urol. 2026 May 5. doi: 10.1038/s41585-026-01150.
    PubMed        
    
    
13. GIESEN A, den Hartog J, Van Goubergen J, Rans K, et al
    Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.
    Nat Rev Urol. 2026 May 6. doi: 10.1038/s41585-026-01144.
    PubMed         Abstract available
    
    

    
    Oncogene

14. ZHANG H, Liu TT, Wu F, Colah AN, et al
    Molecular insights into DDX3X-androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer.
    Oncogene. 2026 May 4. doi: 10.1038/s41388-026-03777.
    PubMed         Abstract available
    
    

    
    PLoS Genet

15. LI Q, Wang D, Zhang Z, Perera D, et al
    Tissue-specific transfer learning improves functional variant and therapeutic target discoveries in breast and prostate cancer.
    PLoS Genet. 2026;22:e1012145.
    PubMed         Abstract available
    
    

    
    PLoS One

16. AZAD BKD, Hakimi AN, Tabatabaei SM, Arezouchi BM, et al
    Automated counting of prostate cell types with image processing and machine learning.
    PLoS One. 2026;21:e0340628.
    PubMed         Abstract available
    
    
17. PRAETZEL L, Burger IA, Ruschoff JH, Rupp NJ, et al
    Dutasteride treatment and its effect on standardized uptake values in prostate-specific membrane antigen-PET imaging: A pilot study.
    PLoS One. 2026;21:e0348695.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

18. LI X, Wang S, Wei Y, Xie C, et al
    AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1.
    Proc Natl Acad Sci U S A. 2026;123:e2534978123.
    PubMed         Abstract available
    
    
19. PARK SK, Lee J, Park SJ, Kim YN, et al
    Functional dissection of SPOP at the amino acid level reveals a comprehensive functional landscape of variants during tumorigenesis.
    Proc Natl Acad Sci U S A. 2026;123:e2523210123.
    PubMed         Abstract available
    
    

    
    Prostate

20. WANG L, Wen X
    Comments on the Study "Evaluating the Efficacy of Barley Water in Alleviating Radiotherapy-Induced Dysuria in Prostate Cancer Patients".
    Prostate. 2026 May 3. doi: 10.1002/pros.70065.
    PubMed        
    
    
21. SU PJ, Lin PH, Lin YH
    Restoration of Mitochondrial Function: A Metabolic Perspective on "Directed Evolution" in Castration-Resistant Prostate Cancer.
    Prostate. 2026 May 3. doi: 10.1002/pros.70059.
    PubMed        
    
    
22. WANG L, Yuan D
    Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy: Comment.
    Prostate. 2026 May 3. doi: 10.1002/pros.70064.
    PubMed        
    
    
23. UMAIR M, Razzaq A
    Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment.
    Prostate. 2026 May 3. doi: 10.1002/pros.70084.
    PubMed        
    
    
24. MALSHY K, Shin J, Hunt TC, Bandari J, et al
    Testicular Cancer Survivorship and Prostate Cancer-New Questions on Risk and Outcomes.
    Prostate. 2026 May 3. doi: 10.1002/pros.70081.
    PubMed        
    
    
25. WEN X
    Comments on the Study "Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer".
    Prostate. 2026 May 3. doi: 10.1002/pros.70083.
    PubMed        
    
    
26. FANG Y, Chen S, Cheng B
    Integrating Clinical and Societal Perspectives on Prostate Cancer Research: Addressing Key Limitations and Future Directions.
    Prostate. 2026 May 3. doi: 10.1002/pros.24916.
    PubMed        
    
    
27. XIE W, Lu K
    Limitations and Implications: Revisiting the Clinical Relevance of Ductal Features in Abiraterone-Treated Prostate Cancer.
    Prostate. 2026 May 3. doi: 10.1002/pros.24896.
    PubMed        
    
    
28. LAUTERT-DUTRA W, Melo CM, Chaves LP, Souza FC, et al
    Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer.
    Prostate. 2026 May 3. doi: 10.1002/pros.70173.
    PubMed         Abstract available
    
    
29. NOAKES J, Wainwright K, Hyams E
    Perioperative Safety and Early Oncologic Outcomes of Salvage Irreversible Electroporation for Radiorecurrent Prostate Cancer.
    Prostate. 2026 May 3. doi: 10.1002/pros.70193.
    PubMed         Abstract available
    
    
30. JANG BS, Chun SJ, Kim JH
    Temporal Patterns and Resolution of Toxicities Following Hypofractionated Salvage Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
    Prostate. 2026 May 3. doi: 10.1002/pros.70178.
    PubMed         Abstract available
    
    
31. GARCIA DE HERREROS M, Rodrigo C, Ferrer-Mileo L, Fernandez-Manas L, et al
    Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis.
    Prostate. 2026 May 3. doi: 10.1002/pros.70174.
    PubMed         Abstract available
    
    
32. SUNADA T, Kamiyama Y, Fujiwara M, Hikami K, et al
    Establishment and Characterization of Patient-Derived Xenograft Organoids for Personalized Treatment of Castration-Resistant Prostate Cancer.
    Prostate. 2026 May 7. doi: 10.1002/pros.70192.
    PubMed         Abstract available
    
    

    
    Urology

33. MADHAVARAM A, Whitman J, McCracken P, Sanborn CJ, et al
    Patient Preferences for Treatment of Intermediate-Risk Prostate Cancer: A Discrete Choice Experiment.
    Urology. 2026 May 18:S0090-4295(26)00209-8. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum